Remune immune response

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 391-398

  Lai, Derhsing ^a   Jones, Taff ^a  

^a Vincogen Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 1661; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT GLYCOPROTEIN GP 160; RECOMBINANT PROTEIN; RG 83894; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; MUSCLE CRAMP; NONHUMAN; RASH; REVIEW; STRUCTURE ACTIVITY RELATION;

AIDS VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HIV INFECTIONS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036224809     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. The Immune Response Corporation regains all rights to HIV immunotherapeutic from Rhône-Poulenc Rorer Inc
2. Rhône-Poulenc Rorer drops Salk HIV vaccine
3. The Immune Response Corp receives approval to resume treatment using the HIV Immunotherapeutic
4. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA and percentage of CD4 cells
5. Long-term follow-up data published on initial patients treated with Remune™
6. Health Professionals Inc announces research agreement
7. The Immune Response Corporation and the National Institute of Health begin first pediatric clinical trial of Remune HIV therapy
8. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1(SF2) gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
9. The Immune Response Corporation announces expanded access program of Remune to treat HIV infection
10. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: Long-term follow-up
11. Human immunodeficiency virus isolated from a serum sample collected in 1976 in central Africa
12. Investigation of the use of β-propiolactone in virus inactivation
13. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins
14. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin
15. Status of betaprone for cold sterilization of biological products
16. Binary ethylenimine as an inactivant by foot and mouse disease virus and its application for vaccine production
17. Status of WHO concerning continuous cell lines as substrates for the production of biologicals
18. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees
19. In vivo reactions of β-propiolactone
20. Inactivation of newcastle disease virus by β-propiolactone
21. SIV vaccines: Current status. The role of the SIV-macaque model in AIDS research
22. Shutting down HIV
23. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
24. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV
25. Nonhuman primate models for AIDS
26. Annual update survey of worldwide HIV, SIV and SHIV challenge studies in vaccinated nonhuman primates
27. Molecular and genetic insights into T-cell antigen receptor structure and function
28. Stimulation of the T-cell antigen receptor induces tyrosine phosphorylation of phospholipase C-γ1
29. Antigen receptors on B lymphocytes
30. B lymphocyte activation accompanies phosphorylation of a 72-kDa protein-tyrosine kinase
31. CD4, CD8 and the TCR-CD3 complex: A novel class of protein-tyrosine kinase receptor
32. Signal transduction by T- and B-cell antigen receptors: Converging structures and concepts
33. The regulation and function of p21ras in T cells
34. Immunology: The ins and outs of antigen processing and peptide presentation
35. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
36. HIV preventative vaccines: Progress to date
37. Prospects for the control of AIDS by immunizing seropositive individuals
38. Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS
39. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
40. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
41. 3 CD4 T lymphocytes (AIDS clinical trials group protocol 137)
42. Immune Response Corp. Viru-Tech Ltd
43. The Immune Response Corporation completes enrollment of 2,500 patient phase III clinical trial of Remune™
44. The Immune Response Corporation and Agouron Pharmaceuticals Inc announce collaboration to commercialize Remune
45. The Immune Response Corporation announces publication of results from Thailand clinical trial
46. Pharmaceutical & Biotechnology Bulletin
47. The Immune Response Corp announces Remune clinical data from phase II combination drug trial
48. Remune, antiretroviral combo passes phase II HIV trial
49. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand
50. A primer on HIV type 1-specific immune function and Remune
51. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection
52. The Immune Response Corp announces a $5 million milestone payment from Agouron Pharmaceuticals Inc
53. Humoral responses post immunization with rgp160: Results from a phase II vaccine therapy trial
54. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative vaccine against AIDS
55. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant
56. Safety and immunogenicity of Remune in HIV infected Thai subjects
57. Do β-chemokines have clinical relevance in HIV infection?
58. β-chemokines and protection from HIV type 1 disease
59. Chemokines: Understanding their role in T-lymphocyte biology
60. Cross-clade immune responses after immunization with a whole killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects
61. Viral load studies in a phase II rgp 160 vaccine therapy trial
62. DSMB/Interim analysis
63. Independent panel recommends concluding clinical endpoint trial of Remune; Agouron Pharmaceuticals Inc and The Immune Response Corporation to pursue alternative regulatory strategy
64. Agouron sees Viracept potential in 600,000 untreated HIV patients in US
65. The Immune Response Corp announces a $5 million milestone payment from Agouron Pharmaceuticals Inc
66. The Immune Response Corp announces Remune clinical trial in South America
67. Study of the Immune Response Corporation's Remune in children suggests sustained reduction of viral load
68. Agouron and Immune Response initiate pivotal trial of Remune, an immune-based therapy for the treatment of HIV infection
69. The Immune Response Corporation presents data suggesting that remune may have an effect on the control of HIV infection
70. The Immune Response Corporation announces the start of a trial to examine the effects of Remune during early-stage HIV-infection
71. The Immune Response Corp receives two US patents on immunotherapeutics for prevention and treatment of retroviral disease
72. The Immune Response Corp announces results from a phase II clinical trial of Remune in Thailand
73. Recent clinical data suggest that Remune may help to rebuild immune system when used alone or in combination with antiviral drugs against AIDS virus
74. The Immune Response Corporation to pursue development of a potential preventive HIV vaccine
75. The Immune Response Corporation and Agouron announce the initiation of a pivotal clinical trial of REMUNE an investigational immune-based therapy for the treatment of HIV infection-The Adult AIDS Clinical Trials Group (AACTG) to conduct multicenter trial
76. The Immune Response Corporation and Agouron Pharmaceuticals Inc announce ACTG study update
77. Interim results in a patient subset indicate that treatment with Remune and antiviral drugs may stimulate 'killer' T cell activity-clinical trial data from phase II Spanish trial reported at the Fifth European Conference on Experimental AIDS Research (ECEAR) 2000
78. Killer T cells against the AIDS virus appear to be activated by combination treatment with Remune (investigational HIV-1 immunogen) and antiviral drugs; Data reported at the 13th International AIDS Conference
79. The Immune Response Corporation Announces the addition of Remune, an investigational therapeutic vaccine for the treatment of primary HIV infection, to the 'QUEST' Study
80. Trinity Medical Group USA announces publication of clinical trial results for its HIV treatment using HIV-1 Immunogen (Remune)
81. Trinity Medical Group USA Inc announces assignment of license agreement for REMUNE
82. Trinity Medical Group USA Inc announces amendment of license agreement with the Immune Response Corporation
83. The Immune Response Corporation announces publication of study suggesting that REMUNE induces HIV-1 specific T helper immune responses that correlate with control of virus
84. Agouron Pharmaceuticals Inc terminates Remune development collaboration
85. Immune response Remune trials to continue after Agouron drops rights
86. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of > 300
87. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)
88. Trinity Medical Group USA announces filing of New Drug Application for HIV treatment, Remune, in Thailand
89. The Immune Response Corporation announces its decision not to proceed with Agouron's Remune Study 202
90. Trinity Medical Group USA announces certification of Remune manufacturing facility